Genetic Dissection and Clinical Features of MODY6 (NEUROD1-MODY).


Journal

Current diabetes reports
ISSN: 1539-0829
Titre abrégé: Curr Diab Rep
Pays: United States
ID NLM: 101093791

Informations de publication

Date de publication:
22 02 2019
Historique:
entrez: 23 2 2019
pubmed: 23 2 2019
medline: 4 12 2019
Statut: epublish

Résumé

MODY6 due to mutations in the gene NEUROD1 is very rare, and details on its clinical manifestation and pathogenesis are scarce. In this review, we have summarized all reported cases of MODY6 diagnosed by genetic testing, and examined their clinical features in detail. MODY6 is a low penetrant MODY, suggesting that development of the disease is affected by genetic modifying factors, environmental factors, and/or the effects of interactions of genetic and environmental factors, as is the case with MODY5. Furthermore, while patients with MODY6 can usually achieve good glycemic control without insulin, when undiagnosed they are prone to become ketotic with chronic hyperglycemia, and microangiopathy can progress. MODY6 may also cause neurological abnormalities such as intellectual disability. MODY6 should be diagnosed early and definitively by genetic testing, so that the correct treatment can be started as soon as possible to prevent chronic hyperglycemia.

Identifiants

pubmed: 30793219
doi: 10.1007/s11892-019-1130-9
pii: 10.1007/s11892-019-1130-9
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
Nerve Tissue Proteins 0
Neurogenic differentiation factor 1 169238-82-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

12

Références

J Diabetes Investig. 2018 Jul;9(4):704-712
pubmed: 29406598
Nat Genet. 1999 Nov;23(3):323-8
pubmed: 10545951
Diabetes. 2003 Feb;52(2):403-8
pubmed: 12540614
Pediatr Diabetes. 2008 Aug;9(4 Pt 2):367-72
pubmed: 18331410
Clin Endocrinol (Oxf). 2009 Jun;70(6):847-53
pubmed: 18811724
Genes Dev. 1999 Jul 1;13(13):1647-52
pubmed: 10398678
PLoS One. 2012;7(4):e34860
pubmed: 22509362
Mol Cell Biochem. 2007 Sep;303(1-2):115-20
pubmed: 17440689
J Neurosci. 2000 May 15;20(10):3714-24
pubmed: 10804213
Diabetologia. 2002 Dec;45(12):1709-12
pubmed: 12488961
Biochem J. 2003 May 1;371(Pt 3):675-86
pubmed: 12540293
Hum Mutat. 2008 Nov;29(11):E271-7
pubmed: 18781616
Clin Endocrinol (Oxf). 2015 Apr;82(4):533-42
pubmed: 25041077
Genes Dev. 1995 Apr 15;9(8):1009-19
pubmed: 7774807
Mol Endocrinol. 2002 May;16(5):1097-107
pubmed: 11981044
Pediatr Diabetes. 2018 Aug;19(5):898-904
pubmed: 29521454
Eur J Med Genet. 2016 Feb;59(2):75-9
pubmed: 26773576
Genes Dev. 1997 Sep 15;11(18):2323-34
pubmed: 9308961
N Engl J Med. 2001 Sep 27;345(13):971-80
pubmed: 11575290
Invest Ophthalmol Vis Sci. 2014 Dec 04;56(1):150-5
pubmed: 25477324
Biochem J. 2003 Dec 15;376(Pt 3):707-15
pubmed: 12962539
Diabetologia. 2001 Nov;44(11):2098-103
pubmed: 11719843
Diabetes. 2010 Sep;59(9):2326-31
pubmed: 20573748
Pediatr Diabetes. 2018 Mar;19(2):236-242
pubmed: 28664602
Diabet Med. 2014 Jun;31(6):721-7
pubmed: 24905847
Diabetes. 2007 Feb;56(2):431-7
pubmed: 17259388

Auteurs

Yukio Horikawa (Y)

Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu city, Gifu, 501-1194, Japan. yhorikaw@gifu-u.ac.jp.

Mayumi Enya (M)

Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu city, Gifu, 501-1194, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH